Analysts Offer Predictions for 23448 (LAB.TO)’s FY2023 Earnings (TSE:LAB)

23448 (LAB.TO) (TSE:LAB) – Equities research analysts at Alliance Global Partners dropped their FY2023 earnings per share (EPS) estimates for shares of 23448 (LAB.TO) in a research report issued on Wednesday, November 15th. Alliance Global Partners analyst A. Grey now expects that the company will earn ($0.04) per share for the year, down from their prior estimate of ($0.01). Alliance Global Partners also issued estimates for 23448 (LAB.TO)’s Q4 2023 earnings at ($0.01) EPS and FY2024 earnings at ($0.02) EPS.

23448 (LAB.TO) Price Performance

About 23448 (LAB.TO)

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies.